Should You Buy This Blue Chip Dividend Stock?
Financial markets have faced a tough go of it thus far in 2022. Accelerating inflation rates, upcoming interest rate hikes, and geopolitical turmoil amid Russia's invasion of Ukraine have all contributed to the S&P 500's 12% decline year to date.
But not every component of the S&P 500 has fared poorly this year. Pharma stock Bristol-Myers Squibb (NYSE: BMY) has gained 12% year to date. This raises the following question: Has Bristol-Myers rallied too much to still be considered a buy? Let's dig into the stock's fundamentals and valuation to find an answer to this question.
Image source: Getty Images.
Source Fool.com
